Hoth Therapeutics (NASDAQ:HOTH – Get Free Report)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They ...

Hoth Therapeutics (HOTH) announced its intention to submit an Expanded Access application for HT-001, its novel therapeutic candidate for the ...

Hoth Therapeutics Inc., a micro-cap biotech company, saw its stock price surge over 200% on Tuesday to become the top gainer across U.S. exchanges. Trading volume skyrocketed to 665 times its ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies, today announced its intention to submit an Expanded Access application ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced preclinical findings that highlight the potential of Glial Cell Line-Derived Neurotrophic Factor ...

Hoth Therapeutics , Inc. (NASDAQ:HOTH), a biopharmaceutical company, announced today that it has increased the maximum aggregate offering price of its common stock by $5 million under its existing ...

Hoth Therapeutics (HOTH) announced “promising” findings for its novel therapeutic candidate, HT-001, a topical neurokinin 1 receptor ...

"This partnership is instrumental in our efforts to advance HT-KIT, a promising therapeutic aimed at targeting c-Kit in cancer treatments," said Robb Knie, CEO at Hoth Therapeutics. "We are ...

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic ...

With positive progress in ongoing clinical studies, Hoth Therapeutics aims to provide patients access to HT-001 outside of traditional clinical trials through the Expanded Access Program (EAP ...